Amneal Pharmaceuticals, Inc. AMRX
Amneal Pharmaceuticals, Inc. statistics & valuation
Market cap$5.5B
P / E76.3×
P / S1.8×
P / FCF20.4×
Net margin2.4%
FCF margin8.9%
Net debt$2.3B
Net debt / EBITDA5.1×
Enterprise value USD$7.8B
EV / EBITDA17.3×
Earnings yield EBIT/EV5.1%
Return on capital14.1%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% | 31.5% | 21.7% | 43.1% | 50.9% |
| Operating margin | 13.1% | 8.9% | 8.5% | -4.3% | 7.3% | 4.6% | -15.3% | -1.2% | 23.7% |
| Net margin | 2.4% | -4.2% | -3.5% | -12.2% | 0.6% | 3.4% | -37.1% | -1.2% | 0.0% |
| FCF margin | 8.9% | 8.7% | 12.6% | 0.8% | 9.3% | 16.2% | -2.8% | 10.1% | 13.5% |
| Return on assets | 2.0% | -3.3% | -2.4% | -7.1% | 0.3% | 1.7% | -16.5% | -0.5% | 0.0% |
| Return on equity | -101.0% | 106.7% | -419.7% | -90.7% | 3.6% | 19.7% | -174.0% | -2.2% | — |
| Debt / equity | -36.06× | -21.79× | 120.94× | 8.79× | 7.39× | 8.06× | 7.59× | 2.96× | — |
| Current ratio | 2.17 | 1.41 | 1.63 | 1.88 | 2.24 | 2.29 | 2.20 | 2.32 | 2.60 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.